IQVIA (IQV) to Report Q2 Earnings: What's in the Offing?

Q2 Expectations The Research and Development segment's revenues are expected to be $2.1 billion, implying a 1.7% rise from the year-ago reported figure.The top 10 pharmaceutical companies chose IQVIA to support the novel respiratory vaccine development, which could lead to a breakthrough as the vaccine targets several respiratory viruses simultaneously. Such a feat is anticipated to have benefited this segment's revenues.Our estimate for Contract sales and Medical solutions' revenues is pegged at$ 177 milli ...